Cases

Valeant

Investors in Valeant Pharmaceuticals International Inc. common shares and notes brought securities claims against the company and PricewaterhouseCoopers, resolved by settlement.

Stage: Settled

Updates

On November 16, 2020, the Court approved a settlement agreement with Valeant on behalf of all the remaining Defendants to the Action. For more information, please see the Notices of Settlement Approval below.

The motion for settlement approval will be heard on November 16, at 9:30 am, before the Superior Court of Quebec. Members of the public interested in attending this hearing may join it by videoconference, at the link below.

Click here to Join TEAMS meeting

+1 581-319-2194 Canada, Quebec (Charges may apply with this number)
(833) 450-1741 Canada (Toll Free number)
Conference ID : 177 110 814#

Join via videoconference
teams@teams.justice.gouv.qc.ca Conference ID : 1180976201

December 5, 2019 – The Superior Court of Justice for Ontario granted an order dismissing the claim against PwC and discontinuing the balance of the claim. Additionally, the proposed settlement in the Quebec action has now been approved by the Court. For more information about how this might affect you, please view the following document:

Notice of Discontinuance of Class Actions in Ontario (regarding PwC Settlement)

September 9, 2019 – A proposed partial settlement has been reached with PricewaterhouseCoopers on behalf of certain investors in the common shares and notes of Valeant Pharmaceuticals International Inc. A hearing to determine if the settlement will be approved will take place on November 11, 2019. For more details or to opt out of the proposed settlement, please see the below documents or contact Jon Sloan at 1-866-881-2292 ext. 299 or jsloan@rochongenova.com.


Documents



Contact Us

Contact us if you have any questions or if you want to join this case.